• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PYC
Click for more information
2.70% 19.0¢

PYC THERAPEUTICS LIMITED - Charts / Financials

Market Cap $676.5M  ! watchlist Created with Sketch. Add to my watchlist

PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company... PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The Company's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Last update - 00.00am 22/11/2024 (20 minute delay) ?
Day
Open 18.5¢   Day High 19.0¢   Day Low 17.5¢
Daily Volume 2763158
Bids   Sellers
Number Price Volume   Number Price Volume
2 18.5¢ 118941   2 19.0¢ 183634

Directors & Senior Management

Dr. Rohan Hockings Chief Executive Officer, Executive Director
Mr. Andrew Taylor Chief Financial Officer, Joint Company Secretary
Dr. Glenn Noronha Chief Development Officer
Mr. Kevin R. Hart Joint Company Secretary
Mr. Alan Tribe Non-Executive Chairman of the Board
Mr. Jason Haddock Non-Executive Independent Director
Dr. Michael Rosenblatt Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
19.0¢ 		Change
0.005(2.70%) 		Mkt cap ! $676.5M
Open High Low Value Volume
18.5¢ 19.0¢ 17.5¢ $508.8K 2.763M

Buyers (Bids)

No. Vol. Price($)
2 118941 18.5¢
 

Sellers (Offers)

Price($) Vol. No.
19.0¢ 183634 2
View Market Depth
Last trade - 16.10pm 14/11/2024 (20 minute delay) ?

Top Stories

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse The $8.8 billion dollar merger between Sigma Healthcare and Chemist Warehouse is poised to reshape the Australian pharmacy landscape, consolidating power in the hands of two industry giants. But what does this mean for Australians @ greater access to cheaper medicines or the loss of small, commun...
Scientific conference spotlights PYC's work on blindness disease treatment PYC Therapeutics Ltd will have data from its ongoing trial into a drug candidate to treat Retinitis Pigmentosa type 11 presented in Singapore
Panic, paranoia, and gangland politics: HotCopper users react to Dubber's missing $26M HotCopper users have reacted to overnight reports Dubber has seen $26M disappear from its coffers due to organised crime links.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.